Industry Insights

81. The Rise Of HPAPI Molecules

    A growing proportion of the drug development pipeline is made up of more complex, highly potent APIs (HPAPI). Explore trends in highly potent API manufacturing: safe handling, containment and production.

82. New FDA White Paper Ties Quality To Financial Benefits 8/26/2025

    The agency presents as a stepwise approach in which companies can make incremental investments rather than committing large amounts of capital upfront.

83. Here's Why Outsourcing To CDMOs Doubled In 13 Years 10/4/2023

    It might surprise no one that BioPlan Associates' 20th annual survey on manufacturing found an increased dependence on contract manufacturing. The sheer rate at which demand has grown, however, is stunning, and the survey found CDMO capacity is only now starting to catch up with supply.

84. The Ins And Outs Of Modern Barrier Systems For Sterile Manufacturing 6/10/2024

    This article looks at key features of restricted access barrier systems and isolators and discusses some of their applications.

85. Managing Supply Chain Risks Using Relational Risk Analysis 4/5/2024

    In the bio/pharma and medical device industries, you can easily model, understand, and manage supply chain risks using relational risk analysis. Here's how.

86. Innovation For Subcutaneous Delivery Of Large-Volume Complex Biologics 5/9/2024

    Explore the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.

87. Ensuring Stability And Safety In Aseptic Fill/Finish Manufacturing

    Not all CDMOs are suitably equipped to handle aseptic processing and sterile F/F operations on a clinical and a commercial scale while offering robust safety measures and global reach.

88. Shedding Light On Photo-Stability Forced Degradation 11/26/2024

    Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.

89. NIH:OVCAR-3 Human Ovarian Cancer Model 8/26/2025

    Review studies using the NIH:OVCAR-3 model of human ovarian cancer in the subcutaneous setting in NSG mice with multiple standard agents and vehicles. This model has shown reproducible growth.

90. What To Consider For A Modular Facility With Closed Processing 1/2/2024

    The emerging trends in the biopharmaceutical industry are driving an even greater need for modular facilities and closed processing. Learn about the progression toward closed processing and more.